Elutia Inc. Price & Performance (ELUT)

Elutia launched its EluPro Antibiotic-Eluting BioEnvelope at Heart Rhythm 2025 in San Diego, highlighting its use for cardiac device and neurostimulator patients. The product, recently recognized with a 2025 Edison Award, aims to reduce post-surgical infections and is expanding through new group purchasing agreements and clinical studies.123

Elutia reports that global tariffs have not disrupted its operations, attributing stability to its U.S.-centric manufacturing and distribution. Despite a revenue miss last quarter, the company’s domestic strategy shields it from international supply chain risks, even as its shares have faced significant declines this year.45

Elutia’s recent agreement with Advantus Health Partners expands EluPro’s reach, while a newly launched registry study aims to generate real-world evidence for the product. These moves, alongside a strategic partnership with Boston Scientific, position the company for potential recovery after recent financial setbacks.67